REG - Scancell Hlds - Notice of Interim Results

Scancell HoldingsAnnouncement

23/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250123:nRSW3569Ua&default-theme=true

RNS Number : 3569U  Scancell Holdings Plc  23 January 2025

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Notice of Interim Results

 

Scancell Holdings plc (AIM: SCLP), a clinical-stage biopharmaceutical company
developing novel immunotherapies for cancer, will announce its interim results
for the six months ended 31 October 2024 on Thursday 30 January 2025.

 

Dr Phil L'Huillier, Chief Executive Officer, and Sath Nirmalananthan, Chief
Financial Officer, will host a virtual analyst briefing at 14:00 GMT on the
day of the results. There will also be a live webcast and conference call with
a Q&A session, which can be accessed via this link:
https://www.lsegissuerservices.com/spark/ScancellHoldings/events/ed5646ee-d413-404a-8a95-73bfef540393
(https://www.lsegissuerservices.com/spark/ScancellHoldings/events/ed5646ee-d413-404a-8a95-73bfef540393)
.

 

A copy of the presentation and webcast will be shared on the Investor
Relations section of the Company's website at https://scancell.co.uk/
(https://scancell.co.uk/) shortly afterwards.

 

-ENDS-

 

For further information, please contact:

 

Scancell Holdings plc
 
+44 (0) 20 3709 5700

Phil L'Huillier, CEO

Sath Nirmalananthan, CFO

Professor Lindy Durrant, CSO

Dr Jean-Michel Cosséry, Non-Executive Chairman

 

Panmure Liberum Limited (Nominated Advisor and Joint Broker)
            +44 (0) 20 7886 2500

Emma Earl/ Will Goode/ Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

 

WG Partners LLP (Joint Broker)
 
            +44 (0) 20 3705 9330

David Wilson/ Claes Spang/ Satheesh Nadarajah

 

ICR Healthcare
 
               +44 (0) 20 37095700

Mary-Jane Elliott/ Angela Gray/ Lindsey Neville
                            scancell@icrhealthcare.com

 

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer. The Company is building a pipeline of innovative products by utilising
its four technology platforms: Moditope® and ImmunoBody® for vaccines and
GlyMab® and AvidiMab® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope® and
ImmunoBody®) this includes citrullination and homocitrullination of proteins,
whereas its mAb portfolio targets glycans or sugars that are added onto
proteins and / or lipids (GlyMab® ) or enhances the potency of antibodies and
their ability to directly kill tumour cells (AvidiMab® ).

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOREAXFAADDSEFA